GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genxone SA (WAR:GX1) » Definitions » Net Income (Continuing Operations)

Genxone (WAR:GX1) Net Income (Continuing Operations) : zł-3.94 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genxone Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genxone's Net Income (Continuing Operations) for the three months ended in Dec. 2024 was zł-1.47 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was zł-3.94 Mil.


Genxone Net Income (Continuing Operations) Historical Data

The historical data trend for Genxone's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genxone Net Income (Continuing Operations) Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial 7.15 8.77 0.48 -3.72 -3.94

Genxone Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -0.87 -0.83 -0.77 -1.47

Genxone Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-3.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genxone  (WAR:GX1) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Genxone Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Genxone's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genxone Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genxone SA (WAR:GX1) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
N/A
Address
ul. Kobaltowa 6, Zlotniki, Suchy Las, POL, 62-002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.

Genxone Headlines

No Headlines